Vedic Lifesciences is a contract research organization based in Mumbai, India. We recently examined clinical trials conducted in the hemp and cannabinoid space. We analyzed a total of 27 studies whose investigational product included cannabinoid or other hemp products. This report is intended to cover nutraceutical-centric studies that incorporate cannabidiol (CBD) and its derivatives like hemp and CBD oil (different extracts and forms) as the investigational product. <\/p>\n
This report describes our findings regarding: <\/p>\n
Our findings will interest a broad range of industry professionals: <\/p>\n
By attempting to identify the innovative health claims being investigated for specific forms of CBD, this report aims to help R&D teams formulate their functional ingredients or branded supplements using various CBD types and doses, and design unique trials with trending objectives. It also aims to help company managers make informed decisions about marketing their products and planning their growth and to provide companies looking to enter the CBD market with more information on results of recent clinical and preclinical studies. <\/p>\n
In terms of our search methods, we used the clinical trial registry http:\/\/www.clinicaltrials.gov<\/a> instead of a search engine like PubMed, which would only have yielded trends from published studies initiated more than two years ago. By contrast, a clinical trial registry provides more current data, including data on studies not yet completed. <\/p>\n Here are the filters we used in our analysis: <\/p>\n Health Area <\/p>\n Which health concerns is CBD being studied for?As Figure 1 shows, the majority of CBD research is on cognitive support. The primary objective of more than one-third of the studies we analyzed was some aspect of cognitive health. Secondary outcomes included changes in sleep, quality of life, physical activity, and behavioral patterns at baseline and end of the study. Figure 1 also shows that CBD is now being studied for metabolic health (weight management, glucose levels, lipid profiling). <\/p>\n Study Endpoints <\/p>\n Which study endpoints are these CBD studies focusing on? Table 1 provides a detailed look at some of the most common endpoints for health concerns ranging from cognition and metabolism to immunity, heart health, joint health, sleep, sports performance, and more. <\/p>\n Tools and Biomarkers <\/p>\n Which tools and biomarkers did these CBD studies use? Table 2 provides a detailed look at some of the most common tools and biomarkers used in studies for health concerns ranging from cognition and metabolism to immunity, heart health, joint health, sleep, sports performance, and more. <\/p>\n Sample Size <\/p>\n Interest in CBD has led to more than 150 proof-of-concept studies. Approximately 58% of the studies we analyzed had a sample size of fewer than 50 subjects. (See Figure 2) More companies and research institutes are initiating proof-of-concept\/pilot studies on CBD. This would be a space to watch out for. Large-sample-size studies should follow suit based on the data obtained in the studies. <\/p>\n Completion Status <\/p>\n Interestingly, while more than 42% of the studies we analyzed had been completed, no results were highlighted in the clinical trials registry. (See Figure 3) Another fact we noticed is that close to 31% of the studies are currently recruiting. This means that the research on CBD has gained momentum in the last five years. Finally, both types of studiescompleted and in progressencompass a range of health areas, meaning several health claims are substantiated. <\/p>\n Study Duration <\/p>\n More than 53% of the total studies we analyzed had a duration of less than 12 monthswith some still in the recruitment phase in terms of their completion date. (See Figure 4) This fact, combined with a trend observed of smaller study sample sizes, indicates that several companies are interested in faster substantiation of their health claims. This may then lead to large-sample-size studies in the next couple of years and faster market inclusion of their products. <\/p>\n Safety vs. Efficacy Studies <\/p>\n While there are more of proof-of-concept studies, close to 77% of studies are efficacy studies rather than safety studies. This indicates that companies may be directly jumping into substantiating health claims rather than performing the quintessential safety assessment of different extracts of CBD. <\/p>\n Other Interesting Insights <\/p>\n When we analyzed the studiesexcluding those whose status was either withdrawn or unknown, two studies caught our attention, for different reasons. <\/p>\n First, in the study NCT05108220, 1350 female subjects aged 24-44 (working population) were recruited in order to investigate the effect of CBD on subjects anxiety levels. The dose-ranging study included CBD oil and capsules with 0.0%-0.3% THC content. In-Home Usage Tests (IHUT) were done to understand the different CBD compounds effects on anxiety in women. <\/p>\n Second study NCT04777981 was interesting. The focus was the effects of CBD, in combination with red algae, on symptomatic improvement in COVID-19 patients. <\/p>\n Other key takeaways is that interest in CBDs benefits is not just limited to cognition. While cognitive support is a known area of CBD research, interest in other health areas like heart health (hypertension), cancer (symptomatic improvement), sleep quality, immune health, and metabolic health demonstrate broad interest in CBD inclusion in the nutraceutical industry. <\/p>\n Recommendations for Research from a Regulatory Perspective <\/p>\n According to certification and testing firm FoodChain ID, both preclinical and clinical studies are mandated for regulatory submission for any novel food. These include the bacterial reverse mutation test, in vitro micronucleus test in mammalian cells, and a 90-day study. Also for CBD, global standardized guideline tests to be done would be OECD 451,452, 443, and 422. <\/p>\n After preclinical studies are concluded, a safety study in healthy individuals is needed. Safety can be analyzed by assessing the comprehensive metabolic panel, which tests the levels of electrolytes and kidney and liver parameters. Tests can also include lipid profile, hormone profiling for men and women, semen analysis, and inflammatory biomarkers. <\/p>\n Another good practice is understanding the sleep quality, cognitive health, and gut parameters using questionnaires. This data can then be studied in conjunction with the safety tests to draw final conclusions about the effect of CBD in humans. <\/p>\n About the Author <\/p>\n Palak Vaval is Senior Associate Business Development, at Vedic Lifesciences, a contract research organization (CRO) based in India. She caters to North & South American nutraceutical companies claims substantiation requirements. With a Masters degree in Life Sciences (Biotechnology), Vaval has close to a decades worth of experience in sales and digital marketing with respect to the food and nutraceutical industry. <\/p>\n <\/p>\n Read more from the original source: <\/p>\n Analyzing CBD studies: Health concerns, health claims, populations ... - Nutritional Outlook<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Vedic Lifesciences is a contract research organization based in Mumbai, India. We recently examined clinical trials conducted in the hemp and cannabinoid space. We analyzed a total of 27 studies whose investigational product included cannabinoid or other hemp products Continue reading